Johnson & Johnson (NYSE:JNJ) announced positive topline results from a pivotal Phase 3 trial evaluating CAPLYTA® (lumateperone) 42 mg once daily for the treatment of acute manic episodes in adults with bipolar I disorder.
Johnson & Johnson (NYSE:JNJ) secured FDA De Novo authorization for its four-arm OTTAVA robotic surgical system.
A Los Angeles County Superior Court jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $32 million to the family of a California woman who died from pleural mesothelioma, concluding that her fatal cancer was directly caused by decades of exposure to asbestos-contaminated talc in the company's iconic baby powder.
Johnson & Johnson (NYSE:JNJ) offered $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and other talc products caused ovarian cancer.
Johnson & Johnson (NYSE:JNJ) has committed more than $1 billion to expand and modernize its Vision care operations in Jacksonville, Florida, targeting increased capacity for its market-leading ACUVUE®-brand contact lenses.
